RECRUITING

Retinal Blood Flow and Autoregulation

Talk to us

Conditions

Glaucomaretinal blood flowerythrocyte mediated angiographyadaptive optics

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.

Official Title

Direct Measures of Retinal Blood Flow and Autoregulation as Robust Biomarkers for Early Glaucoma

Quick Facts

Study Start:2022-05-23
Study Completion:2026-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05344274

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 88 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. age over 18 years
  2. 2. open angle in gonioscopy (grade 3 or 4 in Shaffer classification)
  3. 3. refractive error within the range of +3.00 to -8.00 diopters (4) best-corrected visual acuity 20/25 or better (5) Individuals recruited will be in one of the 3 groups:
  1. 1. corneal abnormalities or other conditions preventing reliable applanation tonometry
  2. 2. retinal disease affecting retinal nerve fiber layer thickness such as vitreomacular traction as determined by a glaucoma specialist
  3. 3. secondary glaucoma
  4. 4. history of prior ocular surgery other than uncomplicated cataract surgery or laser trabeculoplasty
  5. 5. inability to safely be off of glaucoma medications for 4 weeks
  6. 6. inability to obtain OCT angiography data due to excessive eye motion or inability to fixate
  7. 7. unreliable visual fields
  8. 8. any history of smoking in the past 6 months
  9. 9. cataract greater than lens opacity classification system (LOCS) II Grade≥2
  10. 10. diagnosis of diabetes, hypertension, or other known vascular disorder such as vasculitis

Contacts and Locations

Study Contact

Osamah Saeedi, MD, MS
CONTACT
(410) 328-5929
osaeedi@som.umaryland.edu

Study Locations (Sites)

University of Maryland Faculty Physicians, Inc
Baltimore, Maryland, 21201
United States
University of Maryland Medical Center
Baltimore, Maryland, 21201
United States
University of Maryland, Baltimore
Baltimore, Maryland, 21201
United States
Food and Drug Administration (FDA)
Silver Spring, Maryland, 20903
United States

Collaborators and Investigators

Sponsor: University of Maryland, Baltimore

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-23
Study Completion Date2026-09

Study Record Updates

Study Start Date2022-05-23
Study Completion Date2026-09

Terms related to this study

Keywords Provided by Researchers

  • glaucoma
  • retinal blood flow
  • erythrocyte mediated angiography
  • adaptive optics

Additional Relevant MeSH Terms

  • Glaucoma